Degradation resistant HSP70 formulations and uses thereof
US9937241B2 · kind B2 · utility
0Cited by
6References
13Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Oct 13, 2012 |
| Grant date | Apr 10, 2018 |
| Priority date | — |
| Expiry date | Jan 14, 2034 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61K47/60
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The present invention relates to novel therapies that utilize stabilized exogenous HSP70 for the treatment of disorders or conditions regulated by HSP70 through administration of degradation resistant formulations of HSP70. Furthermore, the present invention is directed to methods comprising the administration of stabilized exogenous HSP70 for use in the treatment of HSP70 related disorders or conditions, for example, for increased endurance or alleviating fatigue syndrome.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.